Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase (clinicaltrials.gov Identifier: 01649856) examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Lugtenburg, Pieternella, Avivi, Irit, Berenschot, Henriette, Ilhan, Osman, Marolleau, Jean Pierre, Nagler, Arnon, Rueda, Antonio, Tani, Monica, Turgut, Mehmet, Osborne, Stuart, Smith, Rodney, Pfreundschuh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664395/
https://www.ncbi.nlm.nih.gov/pubmed/28935843
http://dx.doi.org/10.3324/haematol.2017.173583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664395/
https://www.ncbi.nlm.nih.gov/pubmed/28935843
http://dx.doi.org/10.3324/haematol.2017.173583

Ejemplares similares